Axios reports the figure. Anthropic confirms only that it filed a confidential draft S-1—not public filing terms.
Due diligence that never clocks out
Still holding.
Still right?
Don't hold yesterday's thesis. Know what changed—and what still deserves your conviction today.
We'll be live soonSee the product
Noltra is preparing for launch.
noltra / decision deskEXAMPLE
This happened.
What now?
NBIS · review
Anthropic names AWS Trainium and Google–Broadcom TPU capacity. Supplier benefit still depends on delivery and paid use.
Sector spending is not evidence of an Anthropic contract, realized NBIS revenue, or project cash returns. Those links still need proof.
NBIS · DAILY CLOSE$171.45
Oct 20, 2026FMP end-of-day
Real NBIS closes through Oct 20, 2026. Future values below are illustrative what-if inputs—not Noltra price targets or projected results.
Bear · -35%$111.44Funding tightens · illustrative
Base · +10%$188.59Case holds · illustrative
Bull · +55%$265.75Share consolidates · illustrative
Example event, conclusion and future cases. Current close is dated market history; future values are illustrative, not research or a recommendation.
Find the changeacross the exposure chain
Test the caseagainst contrary evidence
Show the decisionwith dates and sources
THE RESEARCH AFTER THE BUYOpen the answer.
Open the answer.
Then challenge it.
Start with today's decision. Drill into the price context, bull, base, and bear cases, strongest countercase, and evidence trail only when you need them.
noltra / company reviewILLUSTRATIVE
EXAMPLE CONTENT · NOT CURRENT INVESTMENT RESEARCHAll figures use disclosed synthetic inputs
TODAY'S EXAMPLE DECISION
NBISNebius Group
WATCH · THESIS HOLDS
SYNTHETIC INDEX · 15 OBSERVATIONS100 → 117.0
+17.0%Base 100 · range 100–121Example period
Long-term demand remains plausible. Near-term financing and customer economics carry more weight than they did before.
ILLUSTRATIVE VALUATION SCENARIOSBull, base, bear
Five annual cash-flow estimates plus terminal value, discounted to present · not current price targetsSee every synthetic valuation input
Revenue grows for five years; annual cash flow equals revenue × margin. Annual cash flows and year-five cash flow × terminal multiple are discounted to present, then cash is added, debt removed, and the result divided by diluted shares.
- Starting revenue
- $4bn
- Annual growth
- 8%
- Cash-flow margin
- 10%
- Discount rate
- 14%
- Terminal multiple
- 10× cash flow
- Cash / debt
- $2bn / $1bn
- Diluted shares
- 0.25bn
- Starting revenue
- $4bn
- Annual growth
- 20%
- Cash-flow margin
- 18%
- Discount rate
- 11%
- Terminal multiple
- 16× cash flow
- Cash / debt
- $2bn / $1bn
- Diluted shares
- 0.25bn
- Starting revenue
- $4bn
- Annual growth
- 30%
- Cash-flow margin
- 24%
- Discount rate
- 10%
- Terminal multiple
- 20× cash flow
- Cash / debt
- $2bn / $1bn
- Diluted shares
- 0.25bn
Every input and output is invented to demonstrate the interface; none is a current forecast or target.
A customer monetization update raised the importance of utilization and funding conditions.
Committed capacity may stay valuable even if application economics take longer to mature.
WHAT WOULD CHANGE THE VIEW
Contracted demand, utilization, financing terms, and verified deployment changes.
Read the example evidence
Example passage“A customer expects deployment to begin after financing closes.”
InterpretationPossible demand path; not a verified order or issuer impact.
ConditionsFinancing closes · deployment occurs · the watched supplier wins demand.
Separate clocksPublished Oct 17, 09:00 UTC · captured 09:04 · assessed 09:12 (example)
Synthetic interface demonstration only. Figures, prices, weights, passages, clocks, and conclusions are invented—not current Noltra research, measured returns, or investment advice.
LESS FEED. MORE JUDGMENT.
The signal, with its receipts.
Noltra does not replace your judgment. It keeps the research ready when the market tests it.
Only the change
The few updates that can alter the case—not every headline.
Beyond the ticker
Customers, suppliers, financing, policy, rates, and bottlenecks.
Evidence you can inspect
The countercase, source trail, and what would change the view.
PLANSRead every decision.
Read every decision.
Or put your own case to the test.
Starter reads all published research. Research plans add questions and theses of your own.
Starter$20/monthBilled monthly
Know what deserves another look.
We'll be live soonResearch$99/monthBilled monthly
Challenge your own investment case.
We'll be live soonResearch+$200/monthBilled monthly
Keep more cases under review.
We'll be live soonResearch Pro$500/monthBilled monthly
Research a larger set of ideas.
We'll be live soonDaily decisions on covered stocks
Every platform thesis and theme
Track your stocks and mapped exposures
Sources and countercase on every view
Ask questions about the evidenceLimited trial
Your own active theses82050
Research usageStandardHigherHighest
Know what deserves another look.
- Daily decisions on covered stocks
- Every platform thesis and theme
- Track your stocks and mapped exposures
- Sources and countercase on every view
- Limited trialAsk questions about the evidence
- Your own active theses
- Research usage
Challenge your own investment case.
- Daily decisions on covered stocks
- Every platform thesis and theme
- Track your stocks and mapped exposures
- Sources and countercase on every view
- Ask questions about the evidence
- 8Your own active theses
- StandardResearch usage
Keep more cases under review.
- Daily decisions on covered stocks
- Every platform thesis and theme
- Track your stocks and mapped exposures
- Sources and countercase on every view
- Ask questions about the evidence
- 20Your own active theses
- HigherResearch usage
Research a larger set of ideas.
- Daily decisions on covered stocks
- Every platform thesis and theme
- Track your stocks and mapped exposures
- Sources and countercase on every view
- Ask questions about the evidence
- 50Your own active theses
- HighestResearch usage
THE BOUNDARIES
Useful because it is honest.
A focused research product. Clear limits.
What do I get with Starter?
Every published decision and theme, the stocks you track, and the macro view—each with its sources and countercase. Starter includes a limited monthly trial of questions about published evidence, but no private theses or full Research access.
What do the Research plans add?
Questions about the published evidence, and your own theses kept under review: up to 8, 20 or 50 active, by plan. Answers cite published sources. They are research support, not advice.
Does every price move rewrite the thesis?
No. Price and operating evidence stay separate. Valuation remains visibly stale when reviewed evidence is not adequate to refresh it.
Does Noltra cover every stock and source?
No. Today it follows 15 stocks and 4 themes. Missing, stale, or unverified evidence stays visible rather than being presented as complete or real time.
How fresh is the research?
Every view shows when its sources were published and when the conclusion was last reviewed. If research falls behind, the date says so—older research is never presented as a fresh assessment.
Does Noltra tell me when to buy or sell?
No. It is shared research with scenarios, counterarguments, and evidence. It is not personalized investment advice, does not know your situation, and does not execute trades.
A bull case should survive contact with new facts.
We'll be live soon